AR027924A1 - Formulacion y sus usos - Google Patents

Formulacion y sus usos

Info

Publication number
AR027924A1
AR027924A1 ARP010100157A ARP010100157A AR027924A1 AR 027924 A1 AR027924 A1 AR 027924A1 AR P010100157 A ARP010100157 A AR P010100157A AR P010100157 A ARP010100157 A AR P010100157A AR 027924 A1 AR027924 A1 AR 027924A1
Authority
AR
Argentina
Prior art keywords
formulation
Prior art date
Application number
ARP010100157A
Other languages
English (en)
Original Assignee
Allergy Therapeutics Ltd
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9883730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR027924(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergy Therapeutics Ltd, Corixa Corp filed Critical Allergy Therapeutics Ltd
Publication of AR027924A1 publication Critical patent/AR027924A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ARP010100157A 2000-01-14 2001-01-12 Formulacion y sus usos AR027924A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0000891.2A GB0000891D0 (en) 2000-01-14 2000-01-14 Formulation

Publications (1)

Publication Number Publication Date
AR027924A1 true AR027924A1 (es) 2003-04-16

Family

ID=9883730

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100157A AR027924A1 (es) 2000-01-14 2001-01-12 Formulacion y sus usos

Country Status (15)

Country Link
US (1) US8470331B2 (es)
EP (3) EP2322212A1 (es)
JP (1) JP4648603B2 (es)
AR (1) AR027924A1 (es)
AU (1) AU2001228625A1 (es)
CA (1) CA2397359C (es)
CZ (1) CZ304941B6 (es)
DE (1) DE60139305D1 (es)
DK (1) DK2100616T3 (es)
ES (2) ES2328336T5 (es)
GB (2) GB0000891D0 (es)
HU (1) HU230545B1 (es)
PL (1) PL356963A1 (es)
SK (1) SK288411B6 (es)
WO (1) WO2001051082A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2005115449A1 (en) * 2004-05-28 2005-12-08 Alk-Abelló A/S Method of treating allergy and infection by eliciting an iga antibody response
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
TR201807756T4 (tr) 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9545455B2 (en) * 2009-04-29 2017-01-17 Pravin K. Muniyappa Device and method for the diagnosis of gastrointestinal allergy
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP5650780B2 (ja) 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
JP2023518924A (ja) * 2020-03-24 2023-05-09 チョル アン，ビョン 幼い哺乳動物の粘膜関連伝染性疾病を予防または治療するための血清組成物の製造方法、前記方法によって製造された血清組成物及びその用途
KR102151962B1 (ko) 2020-03-24 2020-09-04 안병철 어린 포유동물의 전염성 질병을 예방 또는 치료하기 위한 혈청 조성물의 제조방법, 상기 방법에 의해 제조된 혈청 조성물 및 이의 용도

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128637A (en) 1966-09-13 1968-09-25 Beecham Group Ltd Influenza vaccine
US3541201A (en) 1968-12-18 1970-11-17 Ethan Alan Brown Novel sodium chloride encapsulated injectionable substances
GB1377074A (en) * 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
GB1492973A (en) 1974-02-16 1977-11-23 Beecham Group Ltd Process for preparing injectable compositions
US4070455A (en) * 1974-02-16 1978-01-24 Beecham Group Limited Process for preparing injectable desensitizing compositions and products thereof in microparticle form
EP0182442B2 (en) 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3521994A1 (de) * 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
US4975420A (en) * 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
FR2621916B1 (fr) * 1987-10-19 1990-03-09 Bioeurope Derives de la l-tyrosine solubles dans l'eau et procede pour leur preparation
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
CA2131442A1 (en) * 1992-03-03 1993-09-04 Seishi Tsuchiya Oral vaccine
ES2143716T3 (es) * 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
BR9405996A (pt) * 1993-03-11 1995-12-19 Secretech Inc Mucoadesivos poliméricos na distribuição de imunógenos em superfícies mucosais
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
ATE196737T1 (de) * 1993-05-25 2000-10-15 American Cyanamid Co Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
JPH09502604A (ja) 1993-08-27 1997-03-18 エンテリック リサーチ ラボラトリーズ インコーポレイテッド Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ抗原、並びにそれらの製造及び利用
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5646115A (en) * 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
WO1996025664A1 (en) 1995-02-17 1996-08-22 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
GB9508785D0 (en) 1995-04-29 1995-06-21 Smithkline Beecham Plc Novel compositions
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
JP2001519781A (ja) 1997-03-10 2001-10-23 バイエル・コーポレーシヨン ワクチンとしてのウシの呼吸器および腸コロナウイルス
TR199902437T2 (xx) * 1997-04-01 2000-01-21 Corixa Corporation Monofosforil lipid A'ya ait sulu im�nolojik adjuvant terkipleri.
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
AU7983198A (en) * 1997-06-23 1999-01-04 Ludwig Institute For Cancer Research Improved methods for inducing an immune response
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
EP1029053A1 (en) * 1997-11-10 2000-08-23 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from mycobacterium tuberculosis
WO1999064074A1 (en) 1998-06-11 1999-12-16 The Trustees Of The University Of Pennsylvania Methods and compositions for delivering proteins to macrophage cells and cells of macrophage derived lineage
CA2330209A1 (en) 1998-06-12 1999-12-23 Smithkline Beecham Biologicals S.A. Recombinant production of toxoplasma sag1 antigen
CA2337823A1 (en) * 1998-06-26 2000-01-06 Bernard Meignier Mucosal targeting immunisation
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
AU4673099A (en) * 1999-02-26 2000-09-14 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
TR200103046T2 (tr) * 1999-04-23 2002-06-21 Pharmexa A/S IL5 aktivitesini düşürmek için yöntem.
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000076476A1 (en) 1999-06-11 2000-12-21 Endorex Corporation Adjuvant-containing polymerized liposomes for oral, mucosal or intranasal vaccination
GB9924529D0 (en) * 1999-10-15 1999-12-15 Smithkline Beecham Biolog Novel compounds
WO2001095914A1 (en) * 2000-06-14 2001-12-20 William Leslie Porter Lipids for modulating immune response
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition

Also Published As

Publication number Publication date
GB2360210A (en) 2001-09-19
ES2328336T5 (es) 2016-06-21
US20030165512A1 (en) 2003-09-04
GB0101035D0 (en) 2001-02-28
SK10412002A3 (sk) 2003-05-02
HUP0203972A3 (en) 2011-02-28
EP1255563A1 (en) 2002-11-13
JP4648603B2 (ja) 2011-03-09
EP2100616B1 (en) 2015-11-25
CA2397359C (en) 2012-06-05
CA2397359A1 (en) 2001-07-19
CZ20022417A3 (cs) 2003-03-12
ES2561360T3 (es) 2016-02-25
GB0000891D0 (en) 2000-03-08
DE60139305D1 (de) 2009-09-03
DK2100616T3 (en) 2016-02-08
EP1255563B2 (en) 2016-03-02
EP2100616A3 (en) 2009-09-23
SK288411B6 (sk) 2016-10-03
EP2100616A2 (en) 2009-09-16
JP2003519669A (ja) 2003-06-24
EP1255563B1 (en) 2009-07-22
CZ304941B6 (cs) 2015-02-04
US8470331B2 (en) 2013-06-25
HUP0203972A2 (hu) 2003-03-28
EP2322212A1 (en) 2011-05-18
HU230545B1 (hu) 2016-11-28
GB2360210B (en) 2004-12-15
PL356963A1 (en) 2004-07-12
WO2001051082A1 (en) 2001-07-19
ES2328336T3 (es) 2009-11-12
AU2001228625A1 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
AR027924A1 (es) Formulacion y sus usos
ID30590A (id) Celana sekali pakai jenis-celana pendek
DE50112013D1 (de) Deodorantien und antiperspirantien
DE60114145D1 (de) Fulvestrant formulierung
AR027938A1 (es) Compuestos uracilo y utilizacion de los mismos
DE60111534D1 (de) Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase-aktivatoren
IS6709A (is) Fljótandi samsetningar metformíns
NO20024099L (no) Lavdose entecavir-formulering og anvendelse
NO20025357L (no) Antranylamider og deres anvendelse som legemidler
ATE263487T1 (de) Flüssige formulierungen
BRPI0208558A2 (pt) preparado de combinação de estrogênio-gestagênio e uso
ID30187A (id) Dongkrak jenis pantagraf
AR028610A1 (es) Composiciones antitranspirantes y/o desodorantes
DE60125415D1 (de) Formeinsatz
NO20030917D0 (no) Anvendelse
NO20025158L (no) Lipidpreparat og anvendelse derav
NO20025510L (no) Dibenzoazulen-derivater samt anvendelse derav
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
DE50107683D1 (de) Knautschelement
DE50100556D1 (de) Knautschelement
DE60102459D1 (de) Lockenwickler
DE60212612D1 (de) Farbige peroxyd- und polyester-formulierungen
ATE268116T1 (de) Mesotrion-formulierungen
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
DE50109033D1 (de) Verdickerformulierung mit verbesserter biologischer Abbaubarkeit

Legal Events

Date Code Title Description
FB Suspension of granting procedure